ONZ excitement5 Mar 2016 10:54
Interesting that one every bb and twitter feed almost there is a buzz for ONZ because the market cap is tiny and they are trying to branch into exciting new bio markets and maybe there is a good case to argue it's cheap.
Then I look (yet again) at my investment in Puri to make sure I'm seeing it correctly. Market cap £12.28 mil, $15.5 mil of cash which equates to £10.89 mil so if you take out the cash that leaves a value of £1.39 mil
And they have a rapidly growing business which has just increased turnover 36% to $23 mil. And this retail business they are looking to float/sell so potential there for another massive increase in cash.
Oh and then that leaves the bio side of the business...in last trading update...I think the trading patterns speak for themselves, all the trades are small impatient sellers now and again and then there is a massive buy which hoovers it all up. Smart money is buying...
The conclusion of the strategic review has been to initiate a drug development program based on PuriCore's patented hypochlorous acid technology and formulations at high concentration. During the review, the Company generated compelling evidence in preclinical studies that these formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology and Ophthalmology, including certain orphan indications. In relevant animal models of disease, for instance, application of the formulations resulted in a statistically significant impact on allergen-induced itch and inflammation associated with atopic dermatitis (including evidence of the inhibition of key cytokines), as well as hyperemia (red eye) associated with allergic conjunctivitis. This work builds upon previous clinical experience with the Company's medical devices in Wound Care and Dermatology.
In parallel to the preclinical work, the Company worked with a leading pharmaceutical consulting firm to complete a comprehensive drug development strategic review. This review, involving influential key opinion leaders (KOLs), focused on unmet medical needs with considerable commercial value and resulted in the development of a product pipeline in several therapeutic areas based on formulations containing the Company's proprietary immunomodulatory technology. In 2016, the Company is continuing formulation development and conducting a series of additional preclinical and toxicology studies in support of the planned Investigational New Drug (IND) filings.
It is expected that, if successful, clinical development and subsequent New Drug Application (NDA) filing(s) with the FDA will lead to novel prescription medicines for commercially attractive and underserved markets. On current timelines, the Company expects to file two IND applications with the FDA in Q1 2017 and commence clinical testing thereafter. The Company has a search underway for a Chief Medical Officer to support these goals